分组1 - Veralto (VLTO) reported quarterly earnings of $0.99 per share, exceeding the Zacks Consensus Estimate of $0.95 per share, and up from $0.89 per share a year ago, representing an earnings surprise of +4.21% [1] - The company achieved revenues of $1.4 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.58%, and an increase from $1.31 billion year-over-year [2] - Over the last four quarters, Veralto has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has underperformed the market with a gain of about 2.2% since the beginning of the year, compared to the S&P 500's gain of 16.9% [3] - The current consensus EPS estimate for the upcoming quarter is $0.97 on revenues of $1.4 billion, and for the current fiscal year, it is $3.80 on revenues of $5.5 billion [7] - The Waste Removal Services industry, to which Veralto belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - Herc Holdings (HRI) reported quarterly earnings of $2.22 per share, exceeding the Zacks Consensus Estimate of $1.83 per share, but down from $4.35 per share a year ago, indicating an earnings surprise of +21.31% [1] - The company generated revenues of $1.3 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.12% and showing a significant increase from $965 million year-over-year [2] - The stock has underperformed, losing approximately 29.6% since the beginning of the year, compared to a 16.9% gain in the S&P 500 [3] Earnings Performance - Over the last four quarters, Herc Holdings has surpassed consensus EPS estimates two times and topped revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is $2.23, with expected revenues of $1.34 billion, and for the current fiscal year, the estimate is $6.32 on $4.46 billion in revenues [7] Market Outlook - The company's earnings outlook is crucial for investors, as it reflects current consensus expectations and any recent changes [4] - The Zacks Rank for Herc Holdings is currently 4 (Sell), indicating expectations of underperformance in the near future [6] - The Transportation - Equipment and Leasing industry, to which Herc Holdings belongs, is ranked in the top 26% of Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - Nucor (NUE) reported quarterly earnings of $2.63 per share, exceeding the Zacks Consensus Estimate of $2.15 per share, and up from $1.49 per share a year ago, representing an earnings surprise of +22.33% [1] - The company achieved revenues of $8.52 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.39%, compared to $7.44 billion in the same quarter last year [2] Financial Performance - Nucor has surpassed consensus EPS estimates three times over the last four quarters [2] - The company has topped consensus revenue estimates four times in the last four quarters [2] - Nucor shares have increased approximately 18.8% year-to-date, outperforming the S&P 500's gain of 15.5% [3] Future Outlook - The sustainability of Nucor's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - Current consensus EPS estimate for the upcoming quarter is $2.06 on revenues of $7.74 billion, and for the current fiscal year, it is $7.58 on revenues of $32.19 billion [7] Industry Context - The Steel - Producers industry is currently ranked in the bottom 35% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Nucor's stock performance [5]

分组1 - Simply Good Foods reported quarterly earnings of $0.46 per share, missing the Zacks Consensus Estimate of $0.48 per share, and down from $0.5 per share a year ago, representing an earnings surprise of -4.17% [1] - The company posted revenues of $369.04 million for the quarter ended August 2025, surpassing the Zacks Consensus Estimate by 0.83%, but down from $375.69 million year-over-year [2] - Simply Good Foods shares have lost about 36% since the beginning of the year, while the S&P 500 has gained 13.9% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.44 on revenues of $350.59 million, and for the current fiscal year, it is $2.03 on revenues of $1.49 billion [7] - The Zacks Industry Rank for Food - Confectionery is currently in the bottom 15% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8] 分组3 - Ahead of the earnings release, the estimate revisions trend for Simply Good Foods was unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Hasbro reported quarterly earnings of $1.68 per share, exceeding the Zacks Consensus Estimate of $1.66 per share, but down from $1.73 per share a year ago, representing an earnings surprise of +1.20% [1] - The company posted revenues of $1.39 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.16% and up from $1.28 billion year-over-year [2] Market Performance - Hasbro shares have increased approximately 34.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 13.9% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.90 on revenues of $1.21 billion, and for the current fiscal year, it is $4.90 on revenues of $4.42 billion [7] - The Zacks Industry Rank for Toys - Games - Hobbies is in the top 14% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] Estimate Revisions - Prior to the earnings release, the estimate revisions trend for Hasbro was favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6]

Company Performance - Origin Bancorp reported quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.89 per share, and down from $0.60 per share a year ago, representing an earnings surprise of -69.66% [1] - The company posted revenues of $109.83 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.66%, compared to year-ago revenues of $90.79 million [2] - Over the last four quarters, Origin Bancorp has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] Market Comparison - Origin Bancorp shares have added about 2.8% since the beginning of the year, while the S&P 500 has gained 14.5% [3] - The current consensus EPS estimate for the coming quarter is $0.85 on revenues of $101.05 million, and $3.23 on revenues of $382.6 million for the current fiscal year [7] Industry Outlook - The Zacks Industry Rank for Banks - Southeast is currently in the top 26% of over 250 Zacks industries, indicating that the industry is performing well [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on CVS Health (CVS), and highlights the importance of using these recommendations in conjunction with other indicators like the Zacks Rank for making informed investment decisions [1][5]. Brokerage Recommendations for CVS Health - CVS Health has an average brokerage recommendation (ABR) of 1.32, indicating a consensus between Strong Buy and Buy, based on recommendations from 25 brokerage firms [2]. - Out of the 25 recommendations, 20 are classified as Strong Buy, accounting for 80%, while 2 are classified as Buy, making up 8% of the total recommendations [2]. Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations have limited success in guiding investors towards stocks with the highest price increase potential [5]. - Analysts from brokerage firms often exhibit a strong positive bias in their ratings due to vested interests, with five "Strong Buy" recommendations for every "Strong Sell" [6][10]. Zacks Rank as an Alternative Indicator - The Zacks Rank categorizes stocks into five groups based on earnings estimate revisions, providing a more reliable indicator of a stock's price performance in the near future [8][11]. - The Zacks Rank is updated more frequently than the ABR, reflecting timely changes in earnings estimates and business trends [13]. Earnings Estimate Revisions for CVS Health - The Zacks Consensus Estimate for CVS Health has increased by 4% over the past month to $6.32, indicating growing optimism among analysts regarding the company's earnings prospects [14]. - This increase in consensus estimates has contributed to a Zacks Rank of 2 (Buy) for CVS Health, suggesting a positive outlook for the stock [15].

Core Viewpoint - Amarin (AMRN) shares have recently declined by 5.4% over the past four weeks, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottoming out, with reduced selling pressure, which could lead to a bullish trend for the stock [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that buyers are starting to emerge after a downtrend [4][5]. - The effectiveness of the hammer pattern is enhanced when used alongside other bullish indicators, as its strength is dependent on its placement on the chart [6]. Fundamental Analysis - There has been a recent upward trend in earnings estimate revisions for Amarin, which is a positive sign for the stock's future performance [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 2%, indicating that analysts expect better earnings than previously predicted [8]. - Amarin currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Costco (COST), and suggests that while the average brokerage recommendation (ABR) indicates a favorable outlook, investors should exercise caution and consider additional analysis tools like the Zacks Rank for better investment decisions [1][5][10]. Brokerage Recommendations - Costco has an average brokerage recommendation (ABR) of 1.95, which is between Strong Buy and Buy, based on recommendations from 33 brokerage firms [2]. - Out of the 33 recommendations, 15 are Strong Buy (45.5%) and 4 are Buy (12.1%) [2]. Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations have limited success in guiding investors towards stocks with the best price increase potential [5]. - Brokerage firms often exhibit a strong positive bias in their ratings due to vested interests, leading to a disproportionate number of Strong Buy recommendations compared to Strong Sell [6][10]. Zacks Rank as an Alternative - The Zacks Rank categorizes stocks into five groups based on earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [8][11]. - The Zacks Rank is distinct from the ABR, as it is a quantitative model based on earnings estimates rather than solely on brokerage recommendations [9]. Current Earnings Estimates for Costco - The Zacks Consensus Estimate for Costco's earnings for the current year remains unchanged at $17.97, indicating steady analyst views on the company's earnings prospects [13]. - The recent consensus estimate change, along with other factors, has resulted in a Zacks Rank of 3 (Hold) for Costco, suggesting a cautious approach despite the favorable ABR [14].

Core Insights - Sutro Biopharma, Inc. reported a quarterly loss of $0.14 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.39, and an improvement from a loss of $0.59 per share a year ago, resulting in an earnings surprise of +64.10% [1] - The company achieved revenues of $63.75 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 293.54%, compared to $25.71 million in the same quarter last year [2] - Sutro Biopharma's stock has declined approximately 55.6% year-to-date, contrasting with the S&P 500's gain of 7.9% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.24 on revenues of $14.66 million, and for the current fiscal year, it is -$1.79 on revenues of $62.76 million [7] Industry Context - Sutro Biopharma operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable industry outlook [8] - The performance of Sutro Biopharma's stock may be influenced by the overall industry trends, as historically, the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Estimate Revisions - The trend of estimate revisions for Sutro Biopharma was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]